I think if we refer back to the Chairman's letter of 27/11/17 it puts this trading halt in a better context. With funds of $26m plus a $6m R&D tax incentive on the way, he stated they had adequate funding through to 2019. His final key statement begins; "The company continues to actively engage potential partners........"
It is likely therefore that this is much more about a pharma or institutional partner that is keen to be committed through to commercialisation. As there is no current need for further funding you would think a slice of the action would be at a reasonable premium. The price rise over the last few days suggest the word may have got out that this is the case. We will have to be patient to find out though.
VLA Price at posting:
77.0¢ Sentiment: Hold Disclosure: Held
